Who
Richard Bartram
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, MBX Biosciences; Chief Financial Officer, Esperion Therapeutics.
In numbers
- Trades disclosed
- 20
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $343K
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 2 Jan 2018
- Last trade
- 2 Feb 2026
- Last filed
- 3 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Feb 2026filed 3 Feb 2026 | MBX MBX BiosciencesBiotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,000 at $0.00 | filing |
| 2 Feb 2026filed 3 Feb 2026 | MBX MBX BiosciencesBiotechnology | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 3 Feb 2025filed 5 Feb 2025 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —95,000 at $0.00 | filing |
| 12 Sep 2024filed 13 Sep 2024 | MBX MBX Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,578 at $0.00 | filing |
| 14 Mar 2022filed 16 Mar 2022 | Esperion Therapeutics | SEC FORM 4 Code A | —37,000 at $0.00 | filing |
| 29 Oct 2021filed 1 Nov 2021 | Esperion Therapeutics | SEC FORM 4 Code A | —18,700 at $0.00 | filing |
| 28 Jun 2021filed 30 Jun 2021 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 28 Jun 2021filed 30 Jun 2021 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code A | —26,400 at $0.00 | filing |
| 28 Jan 2021filed 29 Jan 2021 | Esperion Therapeutics | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 28 Jan 2021filed 29 Jan 2021 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 2 Jan 2020filed 3 Jan 2020 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code A | —33,900 at $0.00 | filing |
| 2 Jan 2020filed 3 Jan 2020 | Esperion Therapeutics | SEC FORM 4 Code A | —7,525 at $0.00 | filing |
| 3 Apr 2019filed 5 Apr 2019 | Esperion Therapeutics | SEC FORM 4 Sold | $278K6,500 at $42.71 | filing |
| 3 Apr 2019filed 5 Apr 2019 | Esperion Therapeutics | SEC FORM 4 Sold | $65K1,500 at $43.62 | filing |
| 28 Nov 2018filed 30 Nov 2018 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 2 Jan 2018filed 3 Jan 2018 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code A | —38,500 at $0.00 | filing |
| 2 Jan 2018filed 3 Jan 2018 | Esperion Therapeuticsoption or derivative | SEC FORM 4 Code M | —17,892 at $0.00 | filing |
| 2 Jan 2018filed 3 Jan 2018 | Esperion Therapeutics | SEC FORM 4 Code M | $66K17,892 at $3.70 | filing |
News
No headline names them, or the companies they trade most, lately.